Form 8-K - Current report:
SEC Accession No. 0000950170-24-131965
Filing Date
2024-12-02
Accepted
2024-12-02 07:15:09
Documents
15
Period of Report
2024-11-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K olma-20241129.htm   iXBRL 8-K 70769
2 EX-4.1 FORM OF PRE-FUNDED AND EXCHANGE WARRANT olma-ex4_1.htm EX-4.1 192906
3 EX-10.1 FORM OF SECURITIES PURCHASE AGREEMENT olma-ex10_1.htm EX-10.1 519188
4 EX-99.1PRESS RELEASE, DATED DECEMBER 2, 2024 olma-ex99_1.htm EX-99.1 27210
5 GRAPHIC img39466132_0.jpg GRAPHIC 175497
  Complete submission text file 0000950170-24-131965.txt   1287511

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT olma-20241129.xsd EX-101.SCH 23853
17 EXTRACTED XBRL INSTANCE DOCUMENT olma-20241129_htm.xml XML 4532
Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39712 | Film No.: 241517401
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)